{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:17:16Z","timestamp":1771478236485,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-025-01896-x","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:02:49Z","timestamp":1756710169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Content Validity of the Spinocerebellar Ataxia Composite Score as a Measure of Disease Progression in Patients with Spinocerebellar Ataxia"],"prefix":"10.1007","volume":"24","author":[{"given":"Michele","family":"Potashman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Rudell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Abetz-Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Suminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinchen","family":"Doma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Jarodia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahak","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Wolfe-Beiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Schmahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"1896_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14737175.2022.2029703","volume":"22","author":"SD Ghanekar","year":"2022","unstructured":"Ghanekar SD, Kuo SH, Staffetti JS, Zesiewicz TA. Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother. 2022;22:101\u201314. https:\/\/doi.org\/10.1080\/14737175.2022.2029703.","journal-title":"Expert Rev Neurother"},{"key":"1896_CR2","doi-asserted-by":"publisher","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266:533 \u201344. https:\/\/doi.org\/10.1007\/s00415-018-9076-4","DOI":"10.1007\/s00415-018-9076-4"},{"key":"1896_CR3","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/acn3.51875","volume":"10","author":"H Jacobi","year":"2023","unstructured":"Jacobi H, Schaprian T, Schmitz-H\u00fcbsch T, Schmid M, Klockgether T. Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset. Ann Clin Transl Neurol. 2023;10:1833\u201343. https:\/\/doi.org\/10.1002\/acn3.51875.","journal-title":"Ann Clin Transl Neurol"},{"issue":"Pt 4","key":"1896_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/121.4.589","volume":"121","author":"T Klockgether","year":"1998","unstructured":"Klockgether T, L\u00fcdtke R, Kramer B, Abele M, B\u00fcrk K, Sch\u00f6ls L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;121(Pt 4):589\u2013600. https:\/\/doi.org\/10.1093\/brain\/121.4.589.","journal-title":"Brain"},{"key":"1896_CR5","volume-title":"GeneReviews","author":"S Perlman","year":"1993","unstructured":"Perlman S. Hereditary ataxia overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews. Seattle, USA: University of Washington; 1993."},{"key":"1896_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.22740","volume":"25","author":"T Schmitz-Hubsch","year":"2010","unstructured":"Schmitz-Hubsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, et al. Self-rated health status in spinocerebellar ataxia\u2013results from a European multicenter study. Mov Disord. 2010;25:587\u201395. https:\/\/doi.org\/10.1002\/mds.22740.","journal-title":"Mov Disord"},{"key":"1896_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s12311-023-01597-3","volume":"23","author":"M Buchholz","year":"2024","unstructured":"Buchholz M, Weber N, R\u00e4dke A, Faber J, Schmitz-H\u00fcbsch T, Jacobi H, et al. Health-related quality of life in patients with spinocerebellar ataxia: a validation study of the EQ-5D-3L. Cerebellum. 2024;23:1020\u201330. https:\/\/doi.org\/10.1007\/s12311-023-01597-3.","journal-title":"Cerebellum"},{"key":"1896_CR8","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s12311-024-01657-2","volume":"23","author":"N Weber","year":"2024","unstructured":"Weber N, Buchholz M, Radke A, Faber J, Schmitz-Hubsch T, Jacobi H, et al. Factors influencing health-related quality of life of patients with spinocerebellar ataxia. Cerebellum. 2024;23:1466\u201377. https:\/\/doi.org\/10.1007\/s12311-024-01657-2.","journal-title":"Cerebellum"},{"key":"1896_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1474-4422(18)30042-5","volume":"17","author":"A Diallo","year":"2018","unstructured":"Diallo A, Jacobi H, Cook A, Labrum R, Durr A, Brice A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018;17:327\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(18)30042-5.","journal-title":"Lancet Neurol"},{"key":"1896_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/acn3.156","volume":"2","author":"ML Monin","year":"2015","unstructured":"Monin ML, Tezenas du Montcel S, Marelli C, Cazeneuve C, Charles P, Tallaksen C, et al. Survival and severity in dominant cerebellar ataxias. Ann Clin Transl Neurol. 2015;2:202\u20137. https:\/\/doi.org\/10.1002\/acn3.156.","journal-title":"Ann Clin Transl Neurol"},{"key":"1896_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/mds.29255","volume":"38","author":"P Moulaire","year":"2023","unstructured":"Moulaire P, Poulet PE, Petit E, Klockgether T, Durr A, Ashisawa T, et al. Temporal dynamics of the scale for the assessment and rating of ataxia in spinocerebellar ataxias. Mov Disord. 2023;38:35\u201344. https:\/\/doi.org\/10.1002\/mds.29255.","journal-title":"Mov Disord"},{"key":"1896_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s40120-024-00661-2","volume":"13","author":"SP Dickson","year":"2024","unstructured":"Dickson SP, Mallinckrodt CH, Rogula B, Powell LC, Potashman MH, Coric V, et al. Development of a general composite scale (GENCOMS) for progressive neurodegenerative diseases and implications for the assessment of disease-modifying therapies. Neurol Ther. 2024;13:1627\u201339. https:\/\/doi.org\/10.1007\/s40120-024-00661-2.","journal-title":"Neurol Ther"},{"key":"1896_CR13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1007\/s12311-024-01697-8","volume":"23","author":"G L\u2019Italien","year":"2024","unstructured":"L\u2019Italien G, Popoff E, Rogula B, Powell L, Potashman M, Dickson S, et al. Development and validation of SCACOMS, a composite scale for assessing disease progression and treatment effects in spinocerebellar ataxia. Cerebellum. 2024;23:2028\u201341. https:\/\/doi.org\/10.1007\/s12311-024-01697-8.","journal-title":"Cerebellum"},{"key":"1896_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3389\/fneur.2020.00902","volume":"11","author":"C-C Lin","year":"2020","unstructured":"Lin C-C, Ashizawa T, Kuo S-H. Collaborative efforts for spinocerebellar ataxia research in the united states: CRC-SCA and READISCA. Front Neurol. 2020;11:902. https:\/\/doi.org\/10.3389\/fneur.2020.00902.","journal-title":"Front Neurol"},{"key":"1896_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/WNL.0b013e31822e7ca0","volume":"77","author":"H Jacobi","year":"2011","unstructured":"Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6. Neurology. 2011;77:1035\u201341. https:\/\/doi.org\/10.1212\/WNL.0b013e31822e7ca0.","journal-title":"Neurology"},{"key":"1896_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","volume":"14","author":"H Jacobi","year":"2015","unstructured":"Jacobi H, du Montcel ST, Bauer P, Giunti P, Cook A, Labrum R, et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015;14:1101\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(15)00202-1.","journal-title":"Lancet Neurol"},{"key":"1896_CR17","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, Food and Drug Administration staff, and other stakeholders. Available at: https:\/\/www.fda.gov\/media\/139088\/download. Accessed January 20, 2025."},{"key":"1896_CR18","doi-asserted-by":"publisher","DOI":"10.4324\/9780203793206","volume-title":"Discovery of grounded theory: strategies for qualitative research","author":"B Glaser","year":"2017","unstructured":"Glaser B. Discovery of grounded theory: strategies for qualitative research. New York, USA: Taylor & Francis; 2017."},{"key":"1896_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health. 2011;14:967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014.","journal-title":"Value Health"},{"key":"1896_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.5688\/aj7408141","volume":"74","author":"C Anderson","year":"2010","unstructured":"Anderson C. Presenting and evaluating qualitative research. Am J Pharm Educ. 2010;74:141. https:\/\/doi.org\/10.5688\/aj7408141.","journal-title":"Am J Pharm Educ"},{"key":"1896_CR21","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/mds.28670","volume":"36","author":"JD Schmahmann","year":"2021","unstructured":"Schmahmann JD, Pierce S, MacMore J, L\u2019Italien GJ. Development and validation of a patient-reported outcome measure of ataxia. Mov Disord. 2021;36:2367\u201377. https:\/\/doi.org\/10.1002\/mds.28670.","journal-title":"Mov Disord"},{"key":"1896_CR22","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1007\/s12311-024-01700-2","volume":"23","author":"M Potashman","year":"2024","unstructured":"Potashman M, Rudell K, Pavisic I, Suminski N, Doma R, Heinrich M, et al. Content validity of the modified functional scale for the assessment and rating of ataxia (f-SARA) instrument in spinocerebellar ataxia. Cerebellum. 2024;23:2012\u201327. https:\/\/doi.org\/10.1007\/s12311-024-01700-2.","journal-title":"Cerebellum"},{"key":"1896_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/mds.29206","volume":"37","author":"W Ilg","year":"2022","unstructured":"Ilg W, Muller B, Faber J, van Gaalen J, Hengel H, Vogt IR, et al. Digital gait biomarkers allow to capture 1-year longitudinal change in spinocerebellar ataxia type 3. Mov Disord. 2022;37:2295\u2013301. https:\/\/doi.org\/10.1002\/mds.29206.","journal-title":"Mov Disord"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-025-01896-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-025-01896-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-025-01896-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T08:32:28Z","timestamp":1758357148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-025-01896-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1896"],"URL":"https:\/\/doi.org\/10.1007\/s12311-025-01896-x","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All eligible individuals with SCA and the HCPs provided informed consent to participate in the interviews and could withdraw at any time. The study was conducted in accordance with the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent and Ethical Approval"}},{"value":"Maggie Heinrich, Katja Rudell, Naomi Suminski, Rinchen Doma, Kavita Jarodia, Mahak Jain, and Chris Buckley are employees of Parexel International and have been compensated as consultants by Biohaven Pharmaceuticals Inc. Linda Abetz-Webb received consultancy fees from Parexel International for this study. Jeremy Schmahmann has received compensation as a consultant for Biohaven Pharmaceuticals Inc., is site Principal Investigator for the Biohaven clinical trials NCT03701399 and NCT02960893, and has received an unrestricted grant from Biohaven for an imaging biomarker study in multiple system atrophy. Susan Perlman has been a member of an advisory board or consultant for Biogen, Biohaven Pharmaceuticals, Inc, Erydel, PTC, Quince Therapeutics, Reata Pharmaceuticals, and Steminent. Liana Rosenthal is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. She engaged in this research as a private consultant or advisor and not in her capacity as a Johns Hopkins faculty member, and was compensated. Liana Rosenthal also receives: research funding support from the NINDS, the Daniel B. and Florence E. Green Family Foundation, and the Macks Family Foundation; programmatic support from the Gordon and Marilyn Macklin Foundation; and salary support for her role as site Principal Investigator for research studies with Biohaven Pharmaceuticals, Pfizer, and EIP Pharma and for serving on the Clinical Events Committee for a research study with Functional Neuromodulation. Liana Rosenthal also serves on steering committees for the Parkinson Study Group\u2019s research study with both UCB and Bial Pharmaceuticals, and on advisory boards for Reata pharmaceuticals, Biogen pharmaceuticals, Biohaven Pharmaceuticals, Merck Healthcare KGaA, and was a one-time consultant for UCB pharmaceuticals.Michele Potashman, Melissa Wolfe-Beiner, Vlad Coric, and Gilbert L\u2019Italien are employed by and hold stock\/stock options in Biohaven Pharmaceuticals Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"146"}}